DEVELOPING · Attributed source report · science · World
Trial results posted: A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
NULLPEN · Source published 11/20/2026, 12:00:00 AM UTCClinicalTrials.gov records the first posting of results for study NCT04175613 on 2026-11-20. A registry posting does not establish that a treatment is effective or safe.
Why it matters
New trial results are available for scrutiny. This report describes the posting only; it does not evaluate the findings.
What remains uncertain
- The study findings have not been independently assessed by NULLPEN.